U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
CoTec Holdings Corp. Announces Partial Settlement and Amendment and Restatement of Convertible Loan Facilities
Westport to Showcase High?Pressure CNG Fuel System for North American Heavy?Duty Fleets at ACT Expo 2026
